RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.
Retrieved on:
Thursday, November 16, 2023
Oncology, Health, Medical Devices, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Medicine, European Journal of Cancer, Gustave Roussy, European Journal, EORTC, Hepatocellular carcinoma, Treatment, Ducreux, ESMO, Gastrointestinal cancer, Research, Medical Affairs Bureau, SAB, LAPC, Gastroenterology, University, Paris-Saclay University, Doctor of Philosophy, Neoplasm, Glomus tumor, Medical imaging, Medical device, Cancer
(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).
Key Points:
- (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).
- Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud.
- Dr. Ducreux earned his master’s degree in biological sciences and PhD in health sciences.
- “I am excited to be working with my distinguished colleagues on RenovoRx’s Scientific Advisory Board,” stated Dr. Ducreux.